These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1569450)

  • 21. [Allogeneic bone marrow transplantation in chronic myeloid leukemia. The clinical results and risk factors in 70 patients].
    Tomás JF; Peñarrubia MJ; García JA; Figuera A; Gómez-García de Soria V; Steegmann JL; Arranz R; Cámara R; Gabriel R; Vázquez L
    Med Clin (Barc); 1995 Nov; 105(16):605-11. PubMed ID: 8523939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.
    Radich JP; Sanders JE; Buckner CD; Martin PJ; Petersen FB; Bensinger W; McDonald GB; Mori M; Schoch G; Hansen JA
    J Clin Oncol; 1993 Feb; 11(2):304-13. PubMed ID: 8426208
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E; Bandini G; Bonini A; Santucci MA; Martinelli G; Rosti G; Testoni N; Zaccaria A; Tura S
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic bone marrow transplantation in children with acute myelogenous leukemia in first remission. Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO).
    Dini G; Boni L; Abla O; Uderzo C; Polchi P; Locatelli F; Di Bartolomeo P; Arcese W; Iori AP; Rossetti F
    Bone Marrow Transplant; 1994 Jun; 13(6):771-6. PubMed ID: 7920313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome.
    Marks DI; Hughes TP; Szydlo R; Kelly S; Cullis JO; Schwarer AP; Mackinnon S; Apperley J; Barrett AJ; Hows JM
    Br J Haematol; 1992 Jul; 81(3):383-90. PubMed ID: 1390211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bone marrow transplantation from unrelated donors in chronic myeloid leukemia: the results in 15 patients].
    Sierra J; Carreras E; Rovira M; Batlle M; Urbano-Ispizua A; Marín P; Besson I; Merino A; Algara M; Cervantes F
    Med Clin (Barc); 1995 May; 104(18):689-94. PubMed ID: 7769878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
    Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
    Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML.
    Schleuning M; Günther W; Tischer J; Ledderose G; Kolb HJ
    Bone Marrow Transplant; 2003 Aug; 32(3):243-50. PubMed ID: 12858194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.
    Ash RC; Casper JT; Chitambar CR; Hansen R; Bunin N; Truitt RL; Lawton C; Murray K; Hunter J; Baxter-Lowe LA
    N Engl J Med; 1990 Feb; 322(8):485-94. PubMed ID: 2300120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
    Zapatero A; Martín de Vidales C; Pinar B; Rodríguez F; Marín A; Cerezo L; Domínguez P; Pérez Torrubia A
    Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.